Skip to content
Screener

EyePoint, Inc. EYPT Stock-Based Comp

Stock-Based Comp at other companies

Merck & Co. logo
Merck & Co.MRK
$298M+38.0%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$243M-3.5%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$15.58M+49.0%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$12.16M-23.5%
Regenxbio logo
RegenxbioRGNX
$9.05M+4.6%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$4.45M-36.3%

Other financials

Income statement

See full
Revenue$507.0K-90.5%
Gross profit$9.8M-30.1%
Operating income-$97.4M-56.5%
Net income-$94.5M-59.0%
EPS (diluted)-$1.09-28.2%

Balance sheet

See full
Cash & equivalents$110.5M+55.3%
Total debt$22.4M-5.7%
Total equity$166.4M-32.4%
Total assets$228.2M-24.2%

Cash flow

See full
Operating cash flow-$62.3M+0.4%
CapEx$1.2M-1.6%
Free cash flow-$63.5M+0.4%

Valuation

See full
Market cap$1.2B+69.1%
Enterprise value$1.11B+67.9%
P/S429.4×+416×

Profitability

See full
Operating margin-11,365.2%-11,754pp
Net margin-10,994.7%-11,355pp
FCF margin-9,726.7%-10,132pp

Returns & leverage

See full
Return on equity-148.7%-13,871pp
Debt / equity0.1×0.0×
Current ratio4.5×-3.5×

Where this comes from

Reported directly by EyePoint, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The source filing: EyePoint, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335037
Line itemSix Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Depreciation of property and equipment1,3261,035
Gain on sale of equity investment(1,302)
Amortization of debt discount and premium and discount on available-for-sale marketable securities(968)(2,934)
Stock-based compensation22,03614,696
Deferred income tax(90)
Changes in operating assets and liabilities:
Accounts receivable and other current assets14,2923,248
Other assets(3,423)(62)

Item 1. Unaudited Financial Statements

FAQ

What is EyePoint, Inc.'s stock-based comp?
EyePoint, Inc. (EYPT) reported stock-based comp of $10.4M in Q2 2026.
How has EyePoint, Inc.'s stock-based comp changed year-over-year?
EyePoint, Inc.'s stock-based comp increased by 51.2% year-over-year, from $6.88M to $10.4M.
What is the long-term trend for EyePoint, Inc.'s stock-based comp?
Over 4 years (2021 to 2025), EyePoint, Inc.'s stock-based comp has grown at a 39.1% compound annual growth rate (CAGR), from $7.45M to $27.87M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Ask your AI about EyePoint, Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude